AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2024
Jan 20, 2024
30751_dirs_2024-01-19_33ba9771-c965-4bc0-ba7a-b9ebe9a14e93.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2024-01-17
Reporting Person: COZADD BRUCE C (Director, Chairman & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-17 | Ordinary Shares | A | 26545 | $0.0 | Acquired | 414303 | Direct |
| 2024-01-17 | Ordinary Shares | F | 12245 | $119.13 | Disposed | 402058 | Direct |
Footnotes
F1: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on May 5, 2021. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2024, which represents the date on which the level of performance attained was certified.
F2: The Reporting Person acquired 137 ordinary shares and 37 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 31, 2023 and November 30, 2023, respectively.
F3: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations.